# A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus

> **NCT07557927** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Kunming Pharmaceuticals, Inc.** · enrollment: 100 (estimated)

## Conditions studied

- Discoid Lupus Erythematosus

## Interventions

- **DRUG:** Dihydroartemisinin tablets
- **DRUG:** Dihydroartemisinin tablets
- **DRUG:** Hydroxychloroquine tablets

## Key facts

- **NCT ID:** NCT07557927
- **Lead sponsor:** Kunming Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2028-09-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07557927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07557927, "A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07557927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*